scholarly journals Clinical Trial Results with the MED-EL Fine Structure Processing Coding Strategy in Experienced Cochlear Implant Users

ORL ◽  
2012 ◽  
Vol 74 (4) ◽  
pp. 185-198 ◽  
Author(s):  
Joachim Müller ◽  
Stefan Brill ◽  
Rudolf Hagen ◽  
Alexander Moeltner ◽  
Steffi-Johanna Brockmeier ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fine Structure ◽  
Cochlear Implant ◽  
Coding Strategy ◽  
Clinical Trial Results

The Nucleus?? 24 Contour??? Cochlear Implant System: Adult Clinical Trial Results

2002 ◽  
Vol 23 (Supplement) ◽  
pp. 41S-48S ◽  
Author(s):  
Aaron J. Parkinson ◽  
Jennifer Arcaroli ◽  
Steven J. Staller ◽  
Patti L. Arndt ◽  
Anne Cosgriff ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cochlear Implant ◽  
Clinical Trial Results ◽  
Implant System ◽  
Nucleus 24

Ataluren: Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

2016 ◽  
Vol 47 (S 01) ◽  
Author(s):  
U. Schara ◽  
C. McDonald ◽  
K. Bushby ◽  
M. Tulinius ◽  
R. Finkel ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Nonsense Mutation ◽  
Clinical Trial Results

Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials

2020 ◽  
Vol 21 ◽  
Author(s):  
Subha Sankar Paul ◽  
Goutam Biswas
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Small Molecule ◽  
Mode Of Action ◽  
Antiviral Drugs ◽  
Public Health Emergency ◽  
Advanced Stage ◽  
Clinical Trial Results

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.

scholarly journals The Disclosure Decision of Foreign Clinical Trials in China: Moderating Effects of Firms’ Contingencies

SAGE Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 215824402110163
Author(s):  
Tariq H. Malik ◽  
Chunhui Huo
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Risk Taking ◽  
Academic Community ◽  
Moderating Effects ◽  
The Public ◽  
Industrial Enterprises ◽  
Unit Increase ◽  
Clinical Trial Results ◽  
Clinical Trial Activity

Result disclosure of clinical trial posts a conflicting logic between private secrecy and public interest. Despite ethical and legal requirements for disclosing clinical trial results, clinical trials’ sponsors tend to withhold the results. We explored the location, timing, and rationale behind the withheld clinical trial results. Based on the entrepreneurial orientation (EO) perspective, we propose that organizational EO contingencies moderate the disclosure decision. We used the completed clinical trial projects in China by foreign and domestic sponsors. First, we found that a unit increase in the sponsor’s experience can increase the disclosure about 1.01 times. Second, we found that industrial enterprises disclose results about 3.7 times more than universities do. Third, we found that foreign clinical trial projects in China tend to disclose 3.9 times more than domestic projects. We link these findings to two types of audience. First, we inform the academic community on the theory and empirics regarding risk-taking behavior in the biopharmaceutical industry’s clinical trial activity. Second, we address the general audiences concerned about the ethical and socioeconomic wellbeing of the public.

scholarly journals Multicenter clinical trial results with the LifeSite® hemodialysis access system

2002 ◽  
Vol 62 (3) ◽  
pp. 1026-1033 ◽  
Author(s):  
Steve J. Schwab ◽  
Mark A. Weiss ◽  
Fred Rushton ◽  
John P. Ross ◽  
Jerry Jackson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hemodialysis Access ◽  
Multicenter Clinical Trial ◽  
Access System ◽  
Clinical Trial Results

Efficacy of SPI-1005 for Prevention of Noise-Induced Hearing Loss: Phase 2 Clinical Trial Results

2014 ◽  
Vol 151 (1_suppl) ◽  
pp. P83-P84 ◽  
Author(s):  
Jonathan Kil ◽  
Eric D. Lynch ◽  
Scott Griffiths ◽  
Edward Lobarinas ◽  
Christopher Spankovich ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hearing Loss ◽  
Noise Induced Hearing Loss ◽  
Phase 2 ◽  
Phase 2 Clinical Trial ◽  
Clinical Trial Results
Sign in / Sign up

Export Citation Format

Share Document